July 22, 2026 · Phase 2 readout
INCY Phase 2 readout: a negative outcome, -6.0%
On July 22, 2026, INCB099280 — Incyte Corporation (Advanced Solid Tumor) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -6.0% in the window around the event. It had already run +13.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$108.53
1d before
$101.98
Event day
$99.75
1d after
$98.22
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -6.0%. Model confidence at the time: 200%.
See the full scored track recordPre-catalyst setup
+13.9%
30-day run-up
3298%
30-day volatility
0.9×
volume spike